Sun Pharma Advanced Research Co Ltd Share Price

India-Uzbekistan Target Doubling Bilateral Trade with New Strategic Business Partnership

At the India-Uzbekistan Business Forum in New Delhi, Union Minister of Commerce and Industry Piyush Goyal urged businesses from both nations to co-invest, co-manufacture, and co-innovate, aiming to double bilateral trade within three years. With two-way trade already reaching around ₹14,473.50 crore ($1.52 billion), the recently concluded Bilateral Investment Treaty (BIT) is poised to bolster investor confidence and unlock long-term capital. The economic partnership seeks to capitalize on India’s expansive domestic market, skilled talent pool, and innovation ecosystem alongside Uzbekistan’s strategic geographical position and abundant natural resources. Key sectors highlighted for strategic cooperation include textiles, pharmaceuticals, healthcare, mining, digital technologies, agriculture, automotive, and advanced manufacturing. Joint efforts will merge Uzbekistan’s rich cotton output with India’s textile processing strengths, alongside driving innovations in medtech, fintech, and Digital Public Infrastructure (DPI). To ensure seamless execution, both nations agreed to dismantle trade barriers, recognize mutual standards, digitalize customs processes, and enhance overall connectivity to boost job creation and solidify their long-term economic alliance.

See More

Market Performance

Source: NSE The Nifty 50 advanced 1.09% to close at 24,334.30, rebounding strongly after the previous session’s subdued performance on broad-based buying across key sectors. The index opened at 24,127.60, touched an intraday low of 24,099.05, and rallied to a high of 24,367.30 before settling near the day’s high, indicating sustained buying interest throughout the session. Market breadth improved significantly, with 37 stocks advancing against 13 declines, reflecting widespread participation in the rally. Within the Nifty 50 universe, buying interest was led by Tech Mahindra (+3.96%), followed by Kotak Mahindra Bank(Nse) (+3.77%),

(+2.99%), Tata Consultancy Svs. (+2.95%), and Icici Bank (+2.52%), indicating strong participation in IT and financial stocks. The rally in frontline technology names and private sector banks suggests renewed investor confidence in growth-oriented sectors, while Jio Financial added further support to the financial space. On the downside, selling pressure was led by (−1.49%), followed by Dr. Reddy's Laboratories (−1.15%), Wipro (Nse) (−1.04%), Sun Pharma ***** (−0.83%), and Apollo ***** (−0.77%), reflecting weakness across metals and healthcare stocks.

See More

Prabhudas Lilladher Maintains Accumulate on Dr Reddy's

Prabhudas Lilladher maintained Accumulate on Dr Reddy's with a ₹1,400 target cutting FY27 estimates by 5% after the company halted Semaglutide supplies due to API impurity issues. Resolution expected by October November 2026. FY28 estimates largely unchanged as the brokerage expects the issue to be temporary. Semaglutide is the active ingredient in blockbuster weight loss and diabetes drugs like Ozempic and Wegovy. Dr Reddy's was developing a generic version a massive opportunity given the global obesity drug boom. Being first to market in countries like Canada gives a significant revenue and market share advantage called first mover advantage. Any delay risks losing this edge to competitors. The API Active Pharmaceutical Ingredient used in Semaglutide had impurity issues. This is a serious quality concern impure drugs cannot be supplied to any regulated market. Dr Reddy's halted supplies voluntarily a responsible move but one that costs significant near-term revenue. ₹180 million of Semaglutide sales are factored into FY28 estimates this number is at risk if resolution takes longer than expected. Dr Reddy's has been reinvesting cash flows from its gRevlimid business into building a pipeline across peptides, biosimilars and GLP products including Semaglutide. This multi year investment cycle is now entering monetisation phase similar to what we saw with Shilpa Medicare. Benefits should be visible from FY27 as new products launch. Dr Reddy's Semaglutide supply halt taught me that pharma companies developing complex drugs face quality and regulatory risks that can temporarily derail near term revenues, and that tracking API quality issues, resolution timelines and first mover advantage windows is essential for evaluating specialty pharma stocks like

, and before investing.

See More

SPARC spent almost 18 months inside a broad consolidation (~₹115–255).

Longer consolidations generally produce stronger moves once they resolve. ✅ 2. Clean Resistance Breakout The major resistance around ₹255 has been broken decisively. Weekly candle has closed well above resistance. ✅ 3. Strong Momentum Candle Breakout candle is large with good range. Indicates institutional buying rather than a marginal breakout. ✅ 4. Volume Expansion The breakout appears accompanied by much higher volume than previous weeks. This is exactly what you want to see. ✅ 5. Little Overhead Supply Between ₹255 and roughly ₹320–340 there isn't much historical congestion. Price can move relatively quickly once momentum continues.

See More

Much more upside

• **SPARC has broken out of a symmetrical triangle**, signaling that the recent consolidation after a strong uptrend may be ending. The breakout candle is accompanied by strong price expansion, improving the probability of trend continuation. • **Support:** ₹205–210 (breakout zone) | **Resistance:** ₹240 initially, followed by the prior swing high near ₹250. Sustaining above the breakout level keeps the bullish structure intact. • The measured move from the triangle projects a **mid-term target zone of ₹280–300+**. As long as SPARC holds above **₹205**, dips may be viewed as pullback opportunities within an ongoing uptrend.

See More

Concord Biotech Gets USFDA Approval Why Regulatory Clearances Can Be a Major Stock Market Trigger

Concord Biotech received USFDA approval for its Mycophenolate Mofetil Oral Suspension, an immunosuppressant drug used to prevent organ rejection in kidney, liver, and heart transplant patients. The approval was granted through the company's Abbreviated New Drug Application (ANDA), allowing it to market the product in the United States. Following the development, the stock remained in focus among investors. Access to the World's Largest Pharma Market The US pharmaceutical market is one of the largest and most profitable in the world. Receiving USFDA approval allows Indian pharmaceutical companies to sell their products in the US and expand their revenue opportunities. Future Revenue Potential Every successful approval adds a new product to a company's portfolio. More approved products can lead to higher sales, better market presence, and stronger long-term growth prospects. Improving Business Outlook Although Jefferies maintained a Hold rating on the stock, the brokerage expects revenue growth and margin improvement in FY27, supported by a healthy order book and new business opportunities. For pharmaceutical companies, regulatory approvals are often as important as quarterly earnings. A company may spend years developing products and obtaining approvals before generating meaningful revenue. Investors closely monitor approvals from regulators such as the USFDA because they can unlock new markets, strengthen competitiveness, and improve future earnings visibility. This news highlights how regulatory approvals can act as long-term growth catalysts for pharmaceutical companies. By tracking companies such as

Concord Biotech, Sun Pharma, Dr. Reddy's Laboratories, and Cipla, investors can understand how product approvals, market expansion, and regulatory developments influence stock performance and future business growth.

See More